Cargando…
Pharmacotherapy Based on ACE2 Targeting and COVID-19 Infection
The new SARS-CoV-2 coronavirus is responsible for the COVID-19 pandemic. A massive vaccination campaign, which is still ongoing, has averted most serious consequences worldwide; however, lines of research are continuing to identify the best drug therapies to treat COVID-19 infection. SARS-CoV-2 pene...
Autores principales: | Vitiello, Antonio, Ferrara, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224264/ https://www.ncbi.nlm.nih.gov/pubmed/35743089 http://dx.doi.org/10.3390/ijms23126644 |
Ejemplares similares
-
Overview of pharmacotherapy targeting COVID-19 disease based on ACE-2: current challenges and future directions
por: Vitiello, Antonio, et al.
Publicado: (2022) -
Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection
por: Vitiello, Antonio, et al.
Publicado: (2021) -
A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?
por: Vitiello, Antonio, et al.
Publicado: (2021) -
The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections
por: Ferrara, Francesco, et al.
Publicado: (2021) -
Efficacy of synthetic glucocorticoids in COVID-19 endothelites
por: Ferrara, Francesco, et al.
Publicado: (2021)